Table 1.
Demographic and clinical characteristics of matched cases and controls
| Controls | Cases | |
|---|---|---|
| n | 37,929 | 37,929 |
| Age (mean (SD)) | 59.36 (19.51) | 59.36 (19.50) |
| 18–39 | 8,545 (22.5) | 8,545 (22.5) |
| 40–64 | 9,052 (23.9) | 9,052 (23.9) |
| 65–79 | 16,194 (42.7) | 16,194 (42.7) |
| 80+ | 4,138 (10.9) | 4,138 (10.9) |
| Male sex | 12,910 (34.0) | 14,780 (39.0) |
| Race | ||
| White/Branca | 21,373 (56.4) | 21,661 (57.1) |
| Brown/Pardo | 6,777 (17.9) | 5,849 (15.4) |
| Black/Preta | 1,583 (4.2) | 1,391 (3.7) |
| Amarela/Yellow | 357 (0.9) | 363 (1.0) |
| Indigenous/Indigena | 5 (0.0) | 13 (0.0) |
| Missing | 7,834 (20.7) | 8,652 (22.8) |
| Healthcare worker | 13,196 (34.8) | 13,196 (34.8) |
| Residence in São Paulo Metropolitan area | 21,231 (56.0) | 21,231 (56.0) |
| No. comorbidities | ||
| None | 27,703 (73.0) | 25,798 (68.0) |
| One-Two | 9,485 (25.0) | 11,032 (29.1) |
| Three or more | 741 (2.0) | 1,099 (2.9) |
| At least one previous visit | 2,751 (7.3) | 1,431 (3.8) |
| Days since 2nd dose | ||
| 0–13 | 4,091 (10.8) | 4,577 (12.1) |
| 14–41 | 8,396 (22.1) | 7,543 (19.9) |
| 42–69 | 7,186 (18.9) | 7,087 (18.7) |
| 70–97 | 6,452 (17.0) | 6,467 (17.1) |
| 98–125 | 5,700 (15.0) | 5,821 (15.3) |
| 126–153 | 3,329 (8.8) | 3,553 (9.4) |
| 154–181 | 2,115 (5.6) | 2,115 (5.6) |
| ≥182 | 660 (1.7) | 766 (2.0) |
| Interdose interval (days) | 24.23 (6.01) | 24.20 (5.49) |
| Interval from 2nd dose to PCR | 72.86 (48.88) | 73.90 (49.57) |
| Interval from symptom onset to PCR | 3.14 (2.29) | 3.87 (2.52) |
| Proportion hospitalised | 5,837 (15.4) | 9,192 (24.2) |
| Proportion died | 1,836 (4.8) | 3,915 (10.3) |